 |
|
The Hope and Fear of Rimonabant
John S. Rumsfeld, MD, PhD;
Brahmajee K. Nallamothu, MD, MPH
JAMA. 2008;299(13):1601-1602. Published online April 1, 2008 (doi:10.1001/jama.299.13.1601).
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
From a patient's perspective, the principal questions about medical therapeutics are "Will I live longer or feel better?" and "What are the risks?" Until answers about the benefits of treatment on meaningful patient outcomes as well as about the attendant treatment risks are available, therapies have no role in the clinical armamentarium. Yet the answers to these deceptively simple questions often remain uncertain, even for some therapies commonly used in medical practice. The 2 faces of uncertainty for new therapeutics are hope and fear. The hope is that a treatment will provide meaningful benefits on patient outcomes. The fear is that, pending robust outcome studies, the only documented "benefits" of treatment may be for surrogate measures that may not translate into better outcomes or that any benefit will come at the expense of unacceptable risks.
Against this background is the . . . [Full Text of this Article]
Author Affiliations: Section of Cardiology, Denver Veterans Affairs Medical Center, Denver, Colorado; Department of Medicine, University of Colorado at Denver, Aurora (Dr Rumsfeld); Section of Cardiology, Ann Arbor Veterans Affairs Medical Center and Department of Medicine, University of Michigan, Ann Arbor (Dr Nallamothu).
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Rimonabant and Progression of Atherosclerosis in Obese Persons
Dora and Scheffel
JAMA 2008;300:280-280.
FULL TEXT
|
